Earnings Preview For Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ: INO) releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Inovio Pharmaceuticals' earnings report.
Earnings and Revenue
Wall Street analysts see Inovio Pharmaceuticals reporting a loss of 30 cents per share on revenue of $7.5 million.
Inovio Pharmaceuticals EPS in the same period a year ago came in at a loss of 35 cents. Sales were $8.5 million. If the company were to match the consensus estimate, earnings would be up 14.29 percent. Revenue would be down 11.56 percent from the year-ago period.
In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | -0.25 | -0.19 | -0.31 | -0.3 |
EPS Actual | -0.4 | -0.13 | -0.31 | -0.35 |
Stock Performance
Over the last 52-week period, shares are down 32.24 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Inovio Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
The Inovio Pharmaceuticals's Q4 conference call is scheduled to begin at 8:00 a.m. ET and can be accessed here: http://ir.inovio.com/news-and-media/news/default.aspx
See more from Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
